These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 15519795

  • 1. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
    Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, Weber KJ, Huber PE.
    Int J Radiat Oncol Biol Phys; 2004 Nov 15; 60(4):1220-32. PubMed ID: 15519795
    [Abstract] [Full Text] [Related]

  • 2. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 3. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy.
    Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Gröne HJ, Debus J, Lipson KE, Abdollahi A.
    Cancer Res; 2005 May 01; 65(9):3643-55. PubMed ID: 15867359
    [Abstract] [Full Text] [Related]

  • 4. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 5. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, Huber PE.
    Cancer Res; 2003 Jul 01; 63(13):3755-63. PubMed ID: 12839971
    [Abstract] [Full Text] [Related]

  • 6. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line.
    Schuuring J, Bussink J, Bernsen HJ, Peeters W, van Der Kogel AJ.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):529-34. PubMed ID: 15667976
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M.
    Clin Cancer Res; 2005 Jul 01; 11(13):4934-40. PubMed ID: 16000592
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.
    Cancer Lett; 2010 Feb 28; 288(2):251-60. PubMed ID: 19664879
    [Abstract] [Full Text] [Related]

  • 9. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, Lipson KE, Peschke P, Debus J, Abdollahi A, Huber PE.
    Strahlenther Onkol; 2006 Jul 28; 182(7):400-7. PubMed ID: 16826359
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.
    Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE.
    Clin Cancer Res; 2005 Sep 01; 11(17):6270-9. PubMed ID: 16144931
    [Abstract] [Full Text] [Related]

  • 11. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3589-97. PubMed ID: 18519793
    [Abstract] [Full Text] [Related]

  • 12. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
    Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B.
    Int J Radiat Oncol Biol Phys; 2006 Aug 01; 65(5):1536-43. PubMed ID: 16863930
    [Abstract] [Full Text] [Related]

  • 13. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
    Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW.
    Lung Cancer; 2004 Dec 01; 46(3):283-91. PubMed ID: 15541812
    [Abstract] [Full Text] [Related]

  • 14. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM, Zhang YM, Fu SB, Liu XH, Fu X, Yu Y, Zhang ZY.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2324-30. PubMed ID: 19080341
    [Abstract] [Full Text] [Related]

  • 15. Angiogenesis inhibition in solid tumors.
    Rosen LS.
    Cancer J; 2001 Nov 20; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [Abstract] [Full Text] [Related]

  • 16. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.
    Clin Cancer Res; 2008 Nov 15; 14(22):7272-83. PubMed ID: 19010843
    [Abstract] [Full Text] [Related]

  • 17. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B.
    Cancer Chemother Pharmacol; 2005 Dec 15; 56(6):569-77. PubMed ID: 16001166
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms for SU5416 as a radiosensitizer of endothelial cells.
    Kim EH, Kim MS, Jeong YK, Cho I, You SH, Cho SH, Lee H, Jung WG, Kim HD, Kim J.
    Int J Oncol; 2015 Oct 15; 47(4):1440-50. PubMed ID: 26314590
    [Abstract] [Full Text] [Related]

  • 19. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B.
    Oncogene; 2005 Aug 18; 24(35):5414-22. PubMed ID: 15940265
    [Abstract] [Full Text] [Related]

  • 20. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, Lu B.
    Cancer Res; 2006 Dec 01; 66(23):11409-15. PubMed ID: 17145887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.